TYMS and breast carcinoma: Likewise, the frequencies of TS 3'-UTR del6 genotype were 45.7% (del6/del6), 42.5% (del6/ins6), and 11.8% (ins6/ins6), respectively, in control subjects and 44.9% (del6/del6), 48.1% (del6/ins6), and 6.9% (ins6/ins6), respectively, in breast cancer patients, and the overall difference was statistically significant (P = 0.026).